Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed (through tissue or cell testing) to have nasopharyngeal carcinoma (a type of cancer affecting the back of the nose and throat) that has come back or spread, and cannot be cured with surgery or radiation therapy. People diagnosed based on imaging and clinical evidence — without a biopsy of the spread — may also be considered.
• People whose cancer got worse during or after first-line platinum-based chemotherapy (a standard type of cancer drug treatment), or whose cancer came back within 6 months of completing platinum-based chemotherapy combined with radiation.
• People aged 18 to 75 years, of any gender.
• People with a general health status rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity — confirm with trial site).
• People with a life expectancy of at least 3 months.
• People who have at least one area of cancer that can be measured using standard imaging methods.
• People whose blood counts and organ function (liver, kidneys, thyroid, and blood clotting) meet specific healthy ranges, without having needed blood transfusions or certain medical supports in the 14 days before joining.
• Women who could potentially become pregnant must have a negative pregnancy test during screening.
• People who are willing and able to provide written consent to participate.

Who may not be able to join:

• People who have had a severe allergic reaction to any of the drugs used in this trial.
• People who have previously been treated with certain targeted cancer drugs called anti-EGFR monoclonal antibodies (such as nimotuzumab or cetuximab) or anti-PD-1 monoclonal antibodies.
• People who currently have another type of cancer in addition to nasopharyngeal carcinoma.
• People who, in the 6 months before screening, experienced a heart attack, severe chest pain, heart bypass surgery, serious heart failure, stroke, mini-stroke, or blood clots in the lungs. People with known heart conditions not meeting those criteria may still be considered if their condition is stable and well managed (confirm with trial site).
• People who have taken an experimental drug within 4 weeks before the trial starts.
• People who have taken high-dose steroids or immune-suppressing medications within 4 weeks before the trial (low-dose or inhaled steroids may be acceptable — confirm with trial site).
• People who have received anti-cancer vaccines or live vaccines within 4 weeks before the trial starts.
• People who have had major surgery or a serious injury within 4 weeks before the trial starts.
• People who are currently enrolled in another interventional clinical trial.
• People with active autoimmune diseases (where the immune system attacks the body) or a history of such diseases that could come back. Some exceptions apply, including controlled type 1 diabetes, thyroid conditions managed with hormone replacement, and certain skin conditions that do not need systemic treatment.
• People with active infections, including active tuberculosis, hepatitis B (unless the virus level is below a specific threshold), hepatitis C (unless confirmed inactive by testing), or HIV.
• People with a history of certain lung conditions, including pulmonary fibrosis, drug-related lung damage, or active lung inflammation seen on a scan during screening.
• People who are legally unable to make their own decisions or give informed consent.
• People with substance abuse or alcohol dependence, or physical or mental health conditions that the trial team believes would prevent safe participation.
• People with other serious medical or mental health conditions — including inflammatory bowel conditions, non-infectious pneumonia, pulmonary fibrosis, dementia, epilepsy, or recent suicidal thoughts or behaviour — that in the trial team's judgement would make participation unsafe or affect the trial results.
• People previously diagnosed with an immune deficiency condition, or with known HIV or AIDS.
• Women who are pregnant or breastfeeding, or anyone of childbearing potential who is unwilling or unable to use contraception throughout the trial and for at least 1 year after treatment ends.
• People whose cancer has returned in the nasopharynx and for whom surgery is considered a suitable treatment option.

Important: Always verify eligibility with the trial site directly before applying.